Follicular Lymphoma

Conference Insider

R-CHOP, Rituximab Maintenance Therapy Extend PFS in Patients With Newly Diagnosed FL

12/05/2020

Rituximab maintenance therapy significantly prolonged PFS in patients with newly diagnosed FL given R-CHOP versus rituximab plus bendamustine, according to data presented at ASH 2020.

Rituximab maintenance therapy...

12/05/2020

Oncology

Videos

Obinutuzumab Plus Venetoclax Well-Tolerated in Previously Untreated FL

07/23/2020

Peter Martin, MD, discussed the findings and clinical significance of the SAKK 35/15 clinical trial.

Peter Martin, MD, discussed the...

07/23/2020

Oncology

News

Update on Upfront and Maintenance Therapy in Follicular Lymphoma

03/23/2019

John P. Leonard, MD, presented an update on upfront and maintenance therapy in follicular lymphoma at the 2019 Great Debates and Updates in Hematologic Malignancies meeting.

John P. Leonard, MD, presented...

03/23/2019

Oncology

News

Lenalidomide Plus Rituximab Improves PFS Among Patients with FL and MZL

12/06/2018

Lenalidomide plus rituximab improves progression-free survival by 54% compared to single-agent rituximab for patients with relapsed or refractory indolent non-Hodgkin lymphoma.

Lenalidomide plus rituximab...

12/06/2018

Oncology

News

Combination Regimen Safe, Effective for Advanced Untreated Follicular Lymphoma

11/30/2018

Lenalidomide combined with obinutuzumab is highly effective for advanced, previously untreated follicular lymphoma while retaining a manageable safety profile, according to study data presented at ASH 2018.

Lenalidomide combined with...

11/30/2018

Oncology

Podcasts

The Past, Present, and Future of Follicular Lymphoma Treatment With John Leonard, MD

11/15/2018

In this 4-part podcast series, John Leonard, MD, discusses the ever changing treatment landscape for follicular lymphoma, and touches upon his research presented at the 2018 ASH Meeting on Hematologic Malignancies.

In this 4-part podcast series,...

11/15/2018

Oncology